Evidence map›Paper›PMID 39142662›Full record

ArticleTropical medicine & international health : TM & IH2024

Compliance with tetracycline eye ointment during annual mass drug administration for trachoma control in the Amhara region, Ethiopia.

Solomon Aragie, Ayalew Shiferaw, Eshetu Sata, Dagnachew Hailu, Adane Dagnew, Taye Zeru, Adisu Abebe, Zerihun Tadesse, Dionna M Wittberg, Isabel J B Thompson and 5 more

Abstract read
In one paragraph

Article in Tropical medicine & international health : TM & IH, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Solomon AragieThe Carter Center Ethiopia, Addis Ababa, Ethiopia.ORCID 0000-0003-4967-9627
Ayalew ShiferawThe Carter Center Ethiopia, Addis Ababa, Ethiopia.
Eshetu SataThe Carter Center Ethiopia, Addis Ababa, Ethiopia.
Dagnachew HailuThe Carter Center Ethiopia, Addis Ababa, Ethiopia.
Adane DagnewThe Carter Center Ethiopia, Addis Ababa, Ethiopia.
Taye ZeruAmhara Public Health Institute, Bahir Dar, Ethiopia.
Adisu AbebeAmhara Regional Health Bureau, Bahir Dar, Ethiopia.
Zerihun TadesseThe Carter Center Ethiopia, Addis Ababa, Ethiopia.
Dionna M WittbergFrancis I Proctor Foundation, University of California, San Francisco, California, USA.
Isabel J B ThompsonFrancis I Proctor Foundation, University of California, San Francisco, California, USA.
Thomas M LietmanFrancis I Proctor Foundation, University of California, San Francisco, California, USA.
Scott D NashThe Carter Center, Atlanta, Georgia, USA.
Kimberly A JensenThe Carter Center, Atlanta, Georgia, USA.
E Kelly CallahanThe Carter Center, Atlanta, Georgia, USA.
Jeremy D KeenanFrancis I Proctor Foundation, University of California, San Francisco, California, USA.

Funding

Sanitation, Water, and Instruction in face-washing for trachoma II (SWIFT II)UG1EY023939 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KEENAN, JEREMY DAVID · 2019 to 2023
$4.1M
Sanitation, Water, and Instruction in Face-washing for TrachomaU10EY023939 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KEENAN, JEREMY DAVID · 2014 to 2018
$2.7M
NEI NIH HHS U10 EY023939NEI NIH HHS UG1 EY023939
6 · The paper itself

Abstract

objectivesA 6-week course of tetracycline eye ointment is an alternative to single -dose oral azithromycin in annual mass drug administration for trachoma control. Compliance with the recommended tetracycline eye ointment regimen has not been well characterised when administered as part of a trachoma control program.

methodsA routine mass drug administration for trachoma was carried out in 40 communities in the Amhara region of Ethiopia. Two tubes of tetracycline eye ointment, to be administered twice daily for 6 weeks, was offered to all children under 6 months of age, to pregnant women who declined to take azithromycin, and to all individuals with a macrolide allergy. Seven weeks following the mass drug administration, a treatment compliance survey was performed for all community members documented to have received tetracycline eye ointment during the mass drug administration.

resultsOf the 491 individuals documented as having received tetracycline eye ointment from the treatment records, 367 completed the survey, of which 214 recalled being offered tetracycline eye ointment. A total of 105 (49%) respondents reported taking ≥1 daily dose of tetracycline eye ointment on most days of the week for at least the first week. Only 20 (9%) respondents reported taking at least 1 tetracycline eye ointment dose per week for 6 weeks. The most common reasons for low compliance included 'saving it for a future infection' and 'stopped because I (or my child) seemed healthy'. The odds of low compliance were greater for those who reported not having adequate counselling (e.g., odds ratio [OR] 5.3, 95% CI 2.5-28.9 when low compliance was defined as not taking a tetracycline eye ointment dose for most days of at least the first week).

conclusionsCompliance with tetracycline eye ointment was low when administered by a trachoma program during a routine mass drug administration, especially for those reporting inadequate counselling. Further research with a larger sample size and varied settings is warranted to better understand and improve compliance.

Indexed as

Anti-Bacterial AgentsMass Drug AdministrationOintmentsTetracyclineTrachomaAdolescentAdultAzithromycinChildChild, PreschoolDrug MonitoringEthiopiaFemaleHumansInfantMaleAnti-Bacterial AgentsAzithromycinOintmentsTetracyclinemass drug administrationtetracycline eye ointmenttrachomatreatment compliance

Identifiers

PMID39142662
PMCPMC12898298

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.